HK$22.46
4.27%
Hong Kong, Mon, Sep 21 2026.
ISIN
KYG4672N1198
Symbol
13

Hutchmed China Target price 2026 - Analyst rating & recommendation

Hutchmed China Classifications & Recommendation

Buy
82%
Hold
18%

Hutchmed China Price Target

Target Price HK$30.55
Price HK$22.46
Potential
Number of Estimates 17
17 Analysts have issued a price target Hutchmed China 2027 . The average Hutchmed China target price is HK$30.55. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 28 analysts: 23 Analysts recommend Hutchmed China to buy, 5 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Hutchmed China stock has an average upside potential 2027 of . Most analysts recommend the Hutchmed China stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion HK$ 4.30 5.04
12.96% 17.11%
EBITDA Margin -4.71% 3.00%
5.30% 163.65%
Net Margin 83.30% 9.28%
1,291.38% 88.86%

21 Analysts have issued a sales forecast Hutchmed China 2026 . The average Hutchmed China sales estimate is

HK$5.0b
unlock
. This is
16.98% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HK$5.8b 33.85%
unlock
, the lowest is
HK$4.3b 0.18%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 HK$4.3b 12.96%
2026
HK$5.0b 17.11%
unlock
2027
HK$5.7b 13.50%
unlock
2028
HK$6.4b 12.76%
unlock
2029
HK$8.3b 29.18%
unlock
2030
HK$15.1b 81.17%
unlock

15 Analysts have issued an Hutchmed China EBITDA forecast 2026. The average Hutchmed China EBITDA estimate is

HK$151m
unlock
. This is
194.02% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
HK$387m 340.56%
unlock
, the lowest is
HK$-63.6m 60.50%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 HK$-203m 17.58%
2026
HK$151m 174.61%
unlock
2027
HK$312m 106.25%
unlock
2028
HK$465m 48.95%
unlock
2029
HK$721m 55.05%
unlock

EBITDA Margin

2025 -4.71% 5.30%
2026
3.00% 163.65%
unlock
2027
5.46% 82.00%
unlock
2028
7.21% 32.05%
unlock
2029
8.65% 19.97%
unlock

22 Hutchmed China Analysts have issued a net profit forecast 2026. The average Hutchmed China net profit estimate is

HK$468m
unlock
. This is
233.28% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HK$2.4b 1,641.52%
unlock
, the lowest is
HK$0.0 100.00%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 HK$3.6b 1,111.03%
2026
HK$468m 86.96%
unlock
2027
HK$708m 51.32%
unlock
2028
HK$1.0b 45.00%
unlock
2029
HK$1.3b 23.61%
unlock

Net Margin

2025 83.30% 1,291.38%
2026
9.28% 88.86%
unlock
2027
12.37% 33.30%
unlock
2028
15.91% 28.62%
unlock
2029
15.22% 4.34%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share HK$ 4.11 0.54
1,108.82% 86.86%
P/E 40.19
EV/Sales 1.78

22 Analysts have issued a Hutchmed China forecast for earnings per share. The average Hutchmed China EPS is

HK$0.54
unlock
. This is
237.50% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
HK$2.80 1,650.00%
unlock
, the lowest is
HK$0.00 100.00%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 HK$4.11 1,108.82%
2026
HK$0.54 86.86%
unlock
2027
HK$0.81 50.00%
unlock
2028
HK$1.18 45.68%
unlock
2029
HK$1.45 22.88%
unlock

P/E ratio

Current 134.63 1,914.56%
2026
40.19 70.15%
unlock
2027
26.56 33.91%
unlock
2028
18.32 31.02%
unlock
2029
14.82 19.10%
unlock

Based on analysts' sales estimates for 2026, the Hutchmed China stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.08
2026
1.78 14.40%
unlock
2027
1.57 11.90%
unlock
2028
1.39 11.32%
unlock
2029
1.08 22.58%
unlock
2030
0.59 44.80%
unlock

P/S ratio

Current
2026
3.77 14.52%
unlock
2027
3.32 11.90%
unlock
2028
2.95 11.31%
unlock
2029
2.28 22.59%
unlock
2030
1.26 44.80%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today